250th ACS Boston, MA – August 16-20, 2015

IntelliSyn will present on the following “Identification of inhibitors of oxygen-sensing transcriptional regulatory elements as modulators of the hypoxia response for the treatment of cancer” and “Development of highly potent, selective BET bromodomain inhibitors that are CNS penetrant and effective in rodent models of brain cancer”.